Get the Stockscreener App
20.01
15.50%
-3.67
Newamsterdam Pharma Company Nv Stock (NAMS) Forecast
The Newamsterdam Pharma Company Nv (NAMS) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $45.88, representing a +129.29% increase from the current price of $20.01. The highest analyst price target is $48.17, and the lowest is $43.59.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month NAMS Price Target
Average 54.92
(+174.48% Upside)
Is Newamsterdam Pharma Company Nv (NAMS) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 43.99 | Neutral |
| STOCH(9,6) | 73.16 | Neutral |
| STOCHRSI(14) | 67.23 | Neutral |
| MACD(12,26) | 1.396 | Sell |
| ADX(14) | 33.79 | Sell |
| William %R | -60.27 | Neutral |
| CCI(14) | -49.31 | Neutral |
Buy: 0
Sell: 2
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
23.89
Sell
|
22.88
Sell
|
| MA20 |
21.34
Sell
|
21.85
Sell
|
| MA50 |
18.90
Buy
|
19.93
Buy
|
| MA100 |
18.26
Buy
|
19.00
Buy
|
| MA200 |
19.49
Buy
|
17.64
Buy
|
Buy: 6
Sell: 4
Neutral: 0
Summary: Buy
According to our latest analysis, NAMS could be considered a Neutral, with 17 technical analysis indicators signaling 6 Buy signals, 6 signaling Sell signals and 5 Neutral signals. This suggests that investors should exercise caution when entering new positions on NAMS, as the market is likely to remain volatile in the near term.
- RSI (Relative Strength Index): The RSI(14) value of 43.99 indicates that NAMS is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 73.16 indicates that NAMS is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 67.23 indicates that NAMS is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 33.79 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -49.31 indicates that NAMS is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term NAMS price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Newamsterdam Pharma Company Nv financial reports and earnings history, Newamsterdam Pharma Company Nv (NAMS) stock could reach $166.58 by 2030, $429.35 by 2040 and $717.31 by 2050. See the projected annual prices until 2050 of the Newamsterdam Pharma Company Nv stock below:
- Newamsterdam Pharma Company Nv (NAMS) is expected to reach an average price of $191.65 in 2035, with a high prediction of $396.24 and a low estimate of $191.09. This indicates an $857.77% rise from the last recorded price of $20.01.
- Newamsterdam Pharma Company Nv (NAMS) stock is projected to chart a bullish course in 2040, with an average price target of $428.64, representing an $2,042% surge from its current level. The forecast ranges from a conservative $397.74 to a sky-high $429.35.
- Our analysts predict Newamsterdam Pharma Company Nv (NAMS) to jump 1,698% by 2045, soaring from $348.65 to an average price of $359.80, potentially reaching $742.83. While $348.65 is the low estimate, the potential upside is significant.
- Newamsterdam Pharma Company Nv (NAMS) stock is expected to climb by 2050, reaching an average of $713.26, a $3,464% jump from its current level. However, a wide range of estimates exists, with high and low targets of $717.31 and $664.11, respectively, highlighting the market's uncertainty.
Newamsterdam Pharma Company Nv Stock (NAMS) Year by Year Forecast
Newamsterdam Pharma Company Nv Stock (NAMS) Price Forecast for 2024
Our forecast for NAMS stock price in 2024 now indicates an average price target of $29.67 with a high forecast of $48.17 and a low forecast of $11.18. The average prediction reflects an increase of +48.30% from the last recorded price of $20.01.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| December, 2024 | $48.07 | $43.59 | $48.17 | +140.25% |
Newamsterdam Pharma Company Nv Stock (NAMS) Price Forecast for 2025
Newamsterdam Pharma Company Nv Stock (NAMS) is expected to reach an average price of $54.92 in 2025, with a high prediction of $76.32 and a low estimate of $33.53. This indicates an +174.48% rise from the last recorded price of $20.01.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $48.10 | $43.39 | $49.59 | +140.37% |
| February, 2025 | $35.14 | $33.53 | $49.66 | +75.62% |
| March, 2025 | $35.76 | $34.75 | $36.87 | +78.73% |
| April, 2025 | $41.89 | $35.09 | $42.59 | +109.36% |
| May, 2025 | $45.22 | $42.55 | $45.52 | +126.01% |
| June, 2025 | $51.03 | $45.56 | $51.36 | +155.03% |
| July, 2025 | $61.69 | $51.10 | $66.99 | +208.27% |
| August, 2025 | $67.96 | $61.91 | $70.11 | +239.62% |
| September, 2025 | $70.37 | $66.90 | $71.36 | +251.68% |
| October, 2025 | $73.82 | $68.56 | $74.38 | +268.91% |
| November, 2025 | $47.48 | $45.65 | $76.32 | +137.27% |
| December, 2025 | $50.12 | $47.17 | $51.01 | +150.48% |
Newamsterdam Pharma Company Nv Stock (NAMS) Price Forecast for 2026
The predicted value for Newamsterdam Pharma Company Nv (NAMS) in 2026 is set at an average of $76.40. Estimates vary from a peak of $102.98 to a trough of $49.82, indicating an +281.82% surge from the present price of $20.01.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $57.53 | $49.82 | $58.28 | +187.53% |
| February, 2026 | $61.71 | $57.30 | $61.99 | +208.39% |
| March, 2026 | $67.66 | $62.04 | $68.38 | +238.14% |
| April, 2026 | $82.56 | $68.79 | $87.32 | +312.57% |
| May, 2026 | $89.70 | $81.90 | $90.30 | +348.27% |
| June, 2026 | $93.06 | $89.19 | $95.03 | +365.08% |
| July, 2026 | $96.56 | $93.53 | $99.18 | +382.54% |
| August, 2026 | $58.33 | $57.77 | $102.98 | +191.50% |
| September, 2026 | $63.19 | $59.56 | $64.40 | +215.77% |
| October, 2026 | $72.22 | $64.41 | $72.87 | +260.93% |
| November, 2026 | $77.63 | $72.94 | $78.11 | +287.94% |
| December, 2026 | $86.49 | $79.02 | $87.21 | +332.25% |
Newamsterdam Pharma Company Nv Stock (NAMS) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Newamsterdam Pharma Company Nv (NAMS) is $105.08, with a high forecast of $140.27 and a low forecast of $69.89. This indicates an +425.13% increase from the last price of $20.01.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $103.59 | $87.99 | $107.64 | +417.69% |
| February, 2027 | $107.97 | $99.91 | $109.73 | +439.60% |
| March, 2027 | $116.74 | $108.80 | $118.71 | +483.41% |
| April, 2027 | $120.38 | $117.58 | $123.97 | +501.58% |
| May, 2027 | $125.28 | $120.92 | $129.64 | +526.08% |
| June, 2027 | $75.74 | $69.89 | $77.70 | +278.49% |
| July, 2027 | $84.51 | $76.95 | $84.95 | +322.35% |
| August, 2027 | $92.68 | $86.17 | $93.14 | +363.17% |
| September, 2027 | $103.31 | $94.43 | $103.77 | +416.29% |
| October, 2027 | $119.25 | $104.66 | $120.05 | +495.94% |
| November, 2027 | $127.65 | $120.61 | $127.96 | +537.95% |
| December, 2027 | $137.49 | $128.07 | $140.27 | +587.13% |
Newamsterdam Pharma Company Nv Stock (NAMS) Price Forecast for 2028
In 2028, Newamsterdam Pharma Company Nv (NAMS) is projected to reach an average price of $132.48, with a high projection of $182.96 and a low estimate of $82.01. This indicates an +562.09% rise from the last price of $20.01.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $144.78 | $139.01 | $148.77 | +623.54% |
| February, 2028 | $153.25 | $144.06 | $154.14 | +665.85% |
| March, 2028 | $88.68 | $82.01 | $156.30 | +343.18% |
| April, 2028 | $95.08 | $89.20 | $95.23 | +375.16% |
| May, 2028 | $109.27 | $97.22 | $109.73 | +446.10% |
| June, 2028 | $119.25 | $111.40 | $119.96 | +495.96% |
| July, 2028 | $134.99 | $120.87 | $135.70 | +574.61% |
| August, 2028 | $149.09 | $136.11 | $149.39 | +645.10% |
| September, 2028 | $161.13 | $149.88 | $162.15 | +705.26% |
| October, 2028 | $170.19 | $160.12 | $170.29 | +750.52% |
| November, 2028 | $179.53 | $169.23 | $180.42 | +797.23% |
| December, 2028 | $99.47 | $94.13 | $182.96 | +397.10% |
Newamsterdam Pharma Company Nv Stock (NAMS) Price Forecast for 2029
The 2029 price forecast for Newamsterdam Pharma Company Nv Stock (NAMS) is $155.60 on average, with a high prediction of $209.62 and a low estimate of $101.57. This represents an +677.59% increase from the previous price of $20.01.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $109.81 | $101.57 | $109.96 | +448.77% |
| February, 2029 | $123.00 | $112.32 | $123.70 | +514.68% |
| March, 2029 | $133.79 | $125.52 | $134.09 | +568.60% |
| April, 2029 | $147.05 | $135.99 | $147.38 | +634.89% |
| May, 2029 | $167.03 | $148.99 | $169.04 | +734.71% |
| June, 2029 | $180.75 | $169.11 | $182.90 | +803.32% |
| July, 2029 | $190.62 | $183.42 | $191.38 | +852.64% |
| August, 2029 | $203.39 | $192.94 | $203.68 | +916.45% |
| September, 2029 | $109.94 | $106.25 | $209.62 | +449.44% |
| October, 2029 | $121.91 | $111.50 | $122.80 | +509.22% |
| November, 2029 | $136.78 | $123.47 | $137.53 | +583.54% |
| December, 2029 | $148.41 | $138.41 | $148.69 | +641.66% |
Newamsterdam Pharma Company Nv Stock (NAMS) Price Forecast for 2030
Newamsterdam Pharma Company Nv Stock (NAMS) is expected to reach an average price of $177.32 in 2030, with a high forecast of $236.28 and a low forecast of $118.37. This signifies an +786.18% surge from the last price of $20.01.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $166.25 | $150.60 | $166.58 | +730.86% |
| February, 2030 | $186.03 | $168.56 | $189.73 | +829.69% |
| March, 2030 | $200.63 | $187.24 | $201.23 | +902.65% |
| April, 2030 | $211.45 | $201.98 | $213.42 | +956.73% |
| May, 2030 | $224.26 | $213.78 | $225.47 | +1,021% |
| June, 2030 | $118.93 | $118.37 | $236.28 | +494.35% |
| July, 2030 | $133.11 | $122.03 | $134.32 | +565.20% |
| August, 2030 | $149.60 | $136.19 | $150.25 | +647.62% |
| September, 2030 | $162.46 | $152.18 | $162.94 | +711.90% |
| October, 2030 | $180.65 | $165.72 | $181.37 | +802.79% |
| November, 2030 | $205.20 | $184.01 | $209.25 | +925.49% |
| December, 2030 | $217.04 | $203.39 | $218.80 | +984.67% |
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):